Obsessive-Compulsive Disorder Research Studies

Clinical Trial for Obsessive Compulsive Disorder

Date: August 19, 2013

This study is being conducted by F. Hoffman-La Roche, Ltd. (Roche) and is under the direction of Dr. Wayne Goodman as the study principle investigator. This study has been approved by name of Institutional Review Board/Ethics Committee, who ensures that the rights of people taking part in clinical studies are protected.

This is a phase II, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838/Bitopertin in combination with Selective Serotonin Reuptake Inhibitors in patients with Obsessive Compulsive Disorder.

Roche wants to check whether patients treated with Bitopertin and a selective serotonin reuptake inhibitor (SSRI) may experience fewer symptoms compared with those treated with SSRI only, a currently recommended treatment for OCD.

Neuroimaging of Olfaction in Obsessive-Compulsive Disorder

Do you have contamination-type OCD?

Date: Oct. 6, 2011

We are investigating the neurocircuitry of basic sensory processing in individuals with contamination-type OCD by examining olfaction during fMRI. Ten people with OCD will be compared to ten matched healthy controls on select measures of emotion, personality and disgust sensitivity, as well as presentation of pleasant and unpleasant smells. Understanding the neural underpinnings of basic sensory deficits in OCD will lead to the development of more effective methods of recognition and treatment for this disorder.

Participants must be between the ages of 18 and 50, right-handed, and in good physical health. Individuals must also have no impairments to their sense of smell, must be able to undergo a one- hour fMRI scan (i.e., no pregnancy or claustrophobia), and have no current or history of neurological illness. Diagnoses of bipolar, psychotic or substance abuse disorders will also exclude individuals from participating. Individuals with OCD must have predominantly contamination concerns and must have a diagnosis of OCD with at least three months of stable symptoms.

Study of Obsessive Compulsive Disorder (OCD)

Age: 18 and olderLocation: San Antonio, Texas

Doctors often begin OCD treatment by giving patients medications such as Anafranil®, Paxil®, Prozac®, Luvox®, or Zoloft®. For some patients, these medications alone are enough to help control their OCD, but for others, these medications do not provide adequate relief of symptoms. For these patients, there is a need for additional treatment options.

In this study, doctors are evaluating two different strengths of the investigational medication, called ondansetron, when it is added to any of the current treatments mentioned above. The results from this study will allow doctors and researchers to better understand the safety and effectiveness of ondansetron when used in combination with these medications, and help to determine whether ondansetron could one day be used as a safe and effective add-on treatment option for OCD patients.

To qualify, you must:

Be 18 years of age or older,

Be diagnosed with OCD,

Be taking one of the following medications: Luvox, Paxil, Prozac or Zoloft,

Still suffering with symptoms of OCD.

If you seem to meet the criteria and you are interested in learning about this study, please call the Clinical Trials of Texas, Inc. office at (210) 949-0122, or send an email to tcritchfield@cttexas.com.

Posted: June 8, 2011

A Pediatric Study of Obsessive Compulsive Disorder (OCD)

Age: 8-17Location:Massachusetts

The Pediatric Psychopharmacology Research Unit at Massachusetts General Hospital (MGH) is conducting a research study that focuses on children affected by Obsessive Compulsive Disorder (OCD).The researchers are looking for children to participate in a pilot study to find out whether the antibiotic Seromycin, or D-Cycloserine (DCS) can boost the effectiveness of cognitive behavioral therapy (CBT), particularly with regard to fear extinction in the treatment of pediatric OCD.

The current study is enrolling children ages 8-17 years old who have OCD. The participation of one parent to accompany the child to all study visits is required. Subjects will randomly (that is, by chance) receive DCS or a placebo (no active drug). This study will involve 10 CBT sessions over 8 weeks. In addition, there will also be 3 assessment visits, which involve structured clinical interviews, blood drawings, a full physical exam, a pregnancy test (if applicable), and the monitoring of participants’ safety. Highly trained clinicians will conduct CBT, and an expert in the field of OCD will conduct all assessment visits.

If a child meets the criteria and you are interested in learning about this study, please call the Pediatric Psychopharmacology office at 617-503-1436, or send an email toeamancuso@partners.org.